News
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
WHO’s new TB numbers highlight an emergency in need of action
“The tuberculosis situation is urgent. TB is again the biggest single killer globally of any infectious disease, including COVID-19. “For
TB Alliance Board of Directors Appoints Two New Members
NEW YORK (Sept 19, 2022)—TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development
TB Alliance Names Pietro Turilli as Head of External Affairs
NEW YORK (June 1, 2022)—TB Alliance today announced the appointment of Pietro Turilli to the position of Senior Vice President
TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis
New Guidelines Have Potential to Transform the TB Treatment Landscape with Six-Month Standard PRETORIA (3 May 2022)—TB Alliance applauds today’s
Advancing the Treatment of Drug-Resistant Tuberculosis this World TB Day
Imagining a TB-free world amidst resurgence during COVID-19 pandemic NEW YORK (March 24, 2022)—The world continues to battle against two
News
Request for Proposals: Clinical Research Organization
Request for Proposal Objective This Request for Proposal has been prepared to facilitate collecting bids from a qualified contract research